Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Cutting-edge prevention drugs - hailed as being able to reduce new infections to zero - could see the end of the Aids ...
Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...
A new generation of nuclear attack submarines is transforming undersea warfare. -This piece profiles the five standout ...